// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

14,049
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 14,049 results Live
FDA AvKARE Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN — AvKARE

# FDA Approves AvKARE's Generic Dapagliflozin AvKARE has received FDA approval for its generic dapagliflozin oral formulation, marking another entry into the competitive SGLT2 inh…

FDA Macleods Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Macleods Pharmaceuticals Limited

# FDA Approves Generic DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Combination Macleods Pharmaceuticals Limited received FDA approval for its generic dapagliflozin and metformin hyd…

FDA Alembic Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN — Alembic Pharmaceuticals Limited

# FDA Approves Generic Dapagliflozin from Alembic Pharmaceuticals The U.S. FDA has approved Alembic Pharmaceuticals Limited's generic dapagliflozin oral formulation, expanding com…

FDA Sun Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries, Inc. secured FDA approval for its oral generic Dapagliflozin and Metformin Hydrochloride tablets, positioning the company to expand its competitive p…

FDA Cipla Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN — Cipla USA Inc.

Cipla USA Inc. secured FDA approval for its generic oral tablet of Dapagliflozin, positioning the manufacturer to capture market share in the growing diabetes treatment sector. Thi…

FDA Biocon Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN — Biocon Pharma Inc.

Biocon Pharma Inc. secured FDA approval for its generic oral formulation of Dapagliflozin via ANDA211470, with the product slated for a market entry in April 2026. This regulatory …

FDA Ascend Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Ascend Laboratories, LLC

Ascend Laboratories received FDA approval for its Generic Dapagliflozin and Metformin Hydrochloride tablets, a critical oral combination therapy for type 2 diabetes. This launch is…

FDA Apotex Apr 6 — 0.00

FDA Approves DAPAGLIFLOZIN — Apotex Corp.

The FDA has granted full approval to generic dapagliflozin manufactured by Apotex Corp., paving the way for the company to capture market share in the widely prescribed SGLT2 inhib…

FDA Baxter Apr 3 — 0.00

FDA Approves PHENYLEPHRINE HYDROCHLORIDE — Baxter Healthcare Corporation

# FDA Approves Baxter Healthcare's Generic Phenylephrine Hydrochloride Injection Baxter Healthcare Corporation has received FDA approval for its generic phenylephrine hydrochlorid…

FDA Sandoz Apr 2 — 0.00

FDA Approves NINTEDANIB — Sandoz Inc

# FDA Approves Sandoz's Generic Nintedanib, Expanding Competition in Pulmonary Fibrosis Market Sandoz Inc. has received FDA approval for its generic nintedanib esylate oral formul…

FDA Dr. Apr 2 — 0.00

FDA Approves NINTEDANIB — Dr. Reddy's Laboratories Inc.

# FDA Approves Dr. Reddy's Laboratories' Generic Nintedanib Dr. Reddy's Laboratories Inc. received FDA approval for its generic nintedanib esylate oral formulation (ANDA219283), m…

FDA Apotex Apr 2 — 0.00

FDA Approves NINTEDANIB — Apotex Corp.

# FDA Approves Generic Version of Nintedanib, Enabling Significant Cost Savings for Pulmonary Fibrosis Patients Apotex Corp. has received FDA approval for a generic formulation of…

FDA EXELAN Apr 2 — 0.00

FDA Approves NINTEDANIB CAPSULES, 100 MG AND 150 MG — EXELAN PHARMACEUTICALS INC.

# FDA Approves Generic Nintedanib Capsules; Exelan Pharmaceuticals Enters Competitive Pulmonary Fibrosis Market Exelan Pharmaceuticals Inc. has received FDA approval for generic n…

FDA Edenbridge Apr 2 — 0.00

FDA Approves NINTEDANIB — Edenbridge Pharmaceuticals LLC.

Edenbridge Pharmaceuticals LLC has received FDA approval for its ANDA219819 application for Nintedanib Esyslate tablets, strengthening the firm’s portfolio with the generic version…

FDA Eli Apr 1 — 0.00

FDA Approves FOUNDAYO — Eli Lilly and Company

# FDA Approves Eli Lilly's FOUNDAYO for Oral Administration Eli Lilly and Company received FDA approval for FOUNDAYO (orforglipron calcium), an oral medication that expands the co…

FDA KLM Mar 31 — 0.00

FDA Approves MESALAMINE — KLM Laboratories Private Limited

# FDA Approves KLM Laboratories' Generic Mesalamine Rectal Formulation KLM Laboratories Private Limited received FDA approval for its generic mesalamine rectal formulation (ANDA22…

FDA ScieGen Mar 31 — 0.00

FDA Approves OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — ScieGen Pharmaceuticals Inc

# FDA Approves Generic Olmesartan Medoxomil and Hydrochlorothiazide Combination ScieGen Pharmaceuticals Inc received FDA approval for a generic version of olmesartan medoxomil and…

FDA Baxter Mar 30 — 0.00

FDA Approves EPINEPHRINE — Baxter Healthcare Corporation

# FDA Approves Baxter Healthcare's Intramuscular Epinephrine Formulation Baxter Healthcare Corporation received FDA approval for its intramuscular epinephrine formulation (NDA2206…

FDA SAGENT Mar 26 — 0.00

FDA Approves Unknown Drug — SAGENT

On March 26, 2026, SAGENT received FDA approval for a new drug, signaling a strategic entry into the market with potential to compete against existing products. The approval is poi…

FDA Denali Mar 24 — 0.00

FDA Approves AVLAYAH — Denali Therapeutics Inc.

# FDA Approves Denali Therapeutics' AVLAYAH, Expanding Its Neurology Portfolio Denali Therapeutics Inc. received FDA approval for AVLAYAH (tividenofusp alfa-eknm), an intravenous …